Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | PLAU | P00749 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.44 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.44 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.44 |
| ▸ | TNKS | O95271 | 1/20 | 0.44 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.44 |
| ▸ | PADI4 | Q9UM07 | 2/20 | 0.44 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.43 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.43 |
| ▸ | ITGAL | P20701 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5883944 | 1.00 | HCAR2 (0.48) | HCAR2RAB9APLAUHDAC3HDAC4 | |
| SCHEMBL1652327 | 0.80 | MET (0.41) | HCAR2RAB9APADI4CYP3A4CYP2C9 | |
| SCHEMBL29302361 | 0.80 | KDM4E (0.50) | HCAR2PADI4KDM4EHSD17B10CA12 | |
| SCHEMBL29137071 | 0.80 | KDM4E (0.50) | HCAR2PADI4KDM4EHSD17B10CA12 | |
| SCHEMBL6152908 | 0.79 | CA12 (0.52) | HCAR2RAB9AHDAC3HDAC4HDAC1 | |
| SCHEMBL6152906 | 0.79 | CA12 (0.52) | HCAR2RAB9AHDAC3HDAC4HDAC1 | |
| SCHEMBL1251511 | 0.78 | HDAC3 (0.52) | HCAR2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL1251510 | 0.78 | HDAC3 (0.52) | HCAR2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL9757071 | 0.78 | HCAR2 (0.48) | HCAR2RAB9AHDAC3HDAC4HDAC1 | |
| SCHEMBL9836170 | 0.78 | HCAR2 (0.48) | HCAR2RAB9AHDAC3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7122551-B2 | Metalloproteinase inhibitor compounds | ASTRAZENECA AB (SE) | 2006-10-17 | — | — | US | disclosed |
| US-20040176386-A1 | Compounds | ASTRAZENECA AB (SE) | 2004-09-09 | — | — | US | disclosed |
| US-6734183-B2 | USEFUL AS METALLOPROTEINASE INHIBITOR; PIPERAZINO-SULFONAMIDE OR PIPERIDINO-SULFONAMIDE COMPOUND | ASTRAZENECA AB (SE) | 2004-05-11 | — | — | US | disclosed |
| EP-1261590-A1 | PIPERIDINE- AND PIPERAZINE SUBSTITUTED N-HYDROXYFORMAMIDES AS INHIBITORS OF METALLOPROTEINASES | AstraZeneca AB (SE) | 2002-12-04 | — | — | EP | disclosed |
| US-20020022628-A1 | Compounds | ASTRAZENECA AB (SE) | 2002-02-21 | — | — | US | disclosed |
| WO-2001062742-A1 | PIPERIDINE- AND PIPERAZINE SUBSTITUTED N-HYDROXYFORMAMIDES AS INHIBITORS OF METALLOPROTEINASES | ASTRAZENECA AB (SE) | 2001-08-30 | — | — | WO | disclosed |
| EP-0210782-B1 | PYRIDINE COMPOUNDS, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Dainippon Pharmaceutical Co., Ltd. (JP) | 1991-04-17 | — | — | EP | disclosed |
| US-4778796-A | ω-(3-pyridyl)alkenamide derivatives and anti-allergenic pharmaceutical compositions containing same | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1988-10-18 | — | — | US | disclosed |
| EP-0210782-A2 | Pyridine compounds, process for the preparation thereof and pharmaceutical composition containing the same | Dainippon Pharmaceutical Co., Ltd. (JP) | 1987-02-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020022628-A1 | Compounds | MMP13, MMP11, MMP3 | HCAR2 1884/4885RAB9A 1875/4885PLAU 105/4885 |
| US-20040176386-A1 | Compounds | MMP13, MMP11, MMP3 | HCAR2 1884/4885RAB9A 1875/4885PLAU 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.